1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0147
    Pefloxacin
    Inhibitor 99.79%
    Pefloxacin is a broad spectrum antibiotic. Pefloxacin blocks DNA replication by inhibiting DNA gyrase. Pefloxacin inhibits DNA relaxation catalyzed by topoisomerase I with an IC50 of 45 μg/mL. Pefloxacin exhibits antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, and Bacteroides fragilis with MIC90s of 0.12, 4, and 16 mg/L, respectively. Pefloxacin has anti-Plasmodium yoelii infection activity. Pefloxacin increase UVA-induced edema and immunesuppression. Pefloxacin can be used for infection studies.
    Pefloxacin
  • HY-P10930A
    wrwycr-NH2 TFA
    98.18%
    wrwycr-NH2 (TFA) is a peptide. wrwycr-NH2 (TFA) is cytotoxic to multiple cancer cells, can induce DNA damage and cell cycle arrest, but does not induce endoplasmic reticulum stress. wrwycr-NH2 (TFA) has anti-tumor activity, and it shows better efficacy when used in combination with DNA-damaging agents.
    wrwycr-NH2 TFA
  • HY-N7523
    Neoxanthin
    Inhibitor
    Neoxanthin is a major xanthophyll carotenoid and a precursor of the plant hormone abscisic acid in dark green leafy vegetables. Neoxanthin is a potent antioxidant and light-harvesting pigment. Neoxanthin induces apoptosis and has anticancer actions.
    Neoxanthin
  • HY-135678
    DHODH-IN-14
    Inhibitor 99.81%
    DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.
    DHODH-IN-14
  • HY-131102
    Mequindox
    Inhibitor 99.67%
    Mequindox is an antimicrobial agent. Mequindox acts as an inhibitor of DNA synthesis. Mequindox induces genotoxicity and carcinogenicity in mice.
    Mequindox
  • HY-162276
    Anticancer agent 188
    99.10%
    Anticancer agent 188 (compound D43) inhibits DNA synthesis in TNBC cells, leading to cell cycle arrest at the G2/M phase. Anticancer agent 188 has anti-cancer viability by inducing ROS-mediated apoptosis and DNA damage.
    Anticancer agent 188
  • HY-135751
    Holomycin
    Holomycin is a secondary metabolite of the dithiolopyrrolone class. Holomycin also is a broad spectrum antibiotic. Holomycin has antitumor activity and can act in vivo on RNA synthesis.
    Holomycin
  • HY-111531
    DMTr-LNA-5MeU-3-CED-phosphoramidite
    98.75%
    DMTr-LNA-5MeU-3-CED-phosphoramidite is a nucleoside derivative.
    DMTr-LNA-5MeU-3-CED-phosphoramidite
  • HY-P10930
    wrwyar-NH2 TFA
    99.41%
    wrwyar-NH2 (TFA) is a control peptide for wrwycr-NH2 (HY-P10930A).
    wrwyar-NH2 TFA
  • HY-114503
    NSAH
    Inhibitor 98.45%
    NSAH is a reversible and competitive nonnucleoside ribonucleotide reductase (RR) inhibitor, with cell-free IC50 of 32 μM and cell-based IC50 of ~250 nM, respectively.
    NSAH
  • HY-150237
    FITC-labeled Drisapersen sodium
    FITC-labeled Drisapersen (sodium) is Drisapersen labeled with FITC. Drisapersen, a antisense oligonucleotide, induces exon 51 skipping during dystrophin pre-mRNA splicing and allows synthesis of partially functional dystrophin in Duchenne muscular dystrophy (DMD) patients with amenable mutations.
    FITC-labeled Drisapersen sodium
  • HY-138601
    5'-O-DMT-N4-Bz-5-Me-dC
    98.72%
    5'-O-DMT-N4-Bz-5-Me-dC is a modified nucleoside. 5'-O-DMT-2'-O-TBDMS-rI can be used in the synthesis of deoxyribonucleic acid or nucleic acid.
    5'-O-DMT-N4-Bz-5-Me-dC
  • HY-W008091R
    5-Methylcytosine (Standard)
    5-Methylcytosine (Standard) is the analytical standard of 5-Methylcytosine (HY-W008091). This product is intended for research and analytical applications. 5-Methylcytosine is a well-characterized DNA modification in prokaryotes and eukaryotes. 5-Methylcytosine forms symmetrical methylation on CpG dinucleotides in DNA, stabilizes tRNA/rRNA structure in RNA, and affects mRNA translation. 5-Methylcytosine can be oxidized to generate 5hmC, 5fC, and 5caC. 5-Methylcytosine can be used in epigenetics, developmental biology, and the study of diseases such as colorectal cancer and hepatocellular carcinoma.
    5-Methylcytosine (Standard)
  • HY-116364
    AZT triphosphate
    Inhibitor
    AZT triphosphate (3'-Azido-3'-deoxythymidine-5'-triphosphate) is a active triphosphate metabolite of Zidovudine (AZT). AZT triphosphate exhibits antiretroviral activity and inhibits replication of HIV. AZT triphosphate also inhibits the DNA polymerase of HBV. AZT triphosphate activates the mitochondria-mediated apoptosis pathway.
    AZT triphosphate
  • HY-160115
    TDP-43 degrader-1
    Inhibitor
    TDP-43 degrader-1 (example 3) reduces the TDP-43 aggregation that can be in the research of Amyotrophic lateral sclerosis and? Alzheimer's disease.
    TDP-43 degrader-1
  • HY-138582
    N6-Methyl-dA phosphoramidite
    99.83%
    N6-Methyl-dA phosphoramidite can be used in the synthesis of oligodeoxyribonucleotides.
    N6-Methyl-dA phosphoramidite
  • HY-125818S6
    Cytidine-5'-triphosphate-15N3 dilithium
    Cytidine-5'-triphosphate-15N3 (Cytidine triphosphate-15N3 dilithium; 5'-CTP-15N3) dilithium is 15N labeled Cytidine-5'-triphosphate (HY-125818). Cytidine 5′-triphosphate (Cytidine triphosphate; 5'-CTP) is a nucleoside triphosphate and serves as a building block for nucleotides and nucleic acids, lipid biosynthesis. Cytidine triphosphate synthase can catalyze the formation of cytidine 5′-triphosphate from uridine 5′-triphosphate (UTP). Cytidine 5′-triphosphate is an essential biomolecule in the de novo pyrimidine biosynthetic pathway in T. gondii.
    Cytidine-5'-triphosphate-<sup>15</sup>N<sub>3</sub> dilithium
  • HY-N0667S
    L-Asparagine-13C4,15N2,d8
    99%
    L-Asparagine-13C4,15N2,d8 is the 13C-labeled and 15N-labeled L-Asparagine (HY-N0667). L-Asparagine is an essential amino acid for leukemic cells and a substrate for L-Asparaginase. L-Asparaginase is a potent anti-leukemic enzyme that promotes asparagine (Asn) and glutamine (Gln) depletion and inhibits protein biosynthesis in lymphoblasts. Removal of L-asparagine from plasma by L-Asparaginase results in inhibition of RNA and DNA synthesis and subsequent apoptosis. L-Asparaginase has cell-killing ability in vitro and in vivo, and selectively inhibits the growth of cancer cells with low asparagine synthetase (AASNS) expression. L-Asparagine can be used as a biomarker and sensor for the study of childhood acute lymphoblastic leukemia.
    L-Asparagine-<sup>13</sup>C<sub>4</sub>,<sup>15</sup>N<sub>2</sub>,d<sub>8</sub>
  • HY-108600
    CGP-53353
    Inhibitor 98.87%
    CGP-53353 (DAPH-7) is an potent PKC inhibitor with IC50s of 0.41 μM and 3.8 μM for PKCβII and PKCβI, respectively. CGP-53353 can inhibit glucose-induced cell proliferation and DNA synthesis in AoSMC and A10 cells. CGP-53353 can be used for researching atherosclerosis of diabetic patients.
    CGP-53353
  • HY-148700
    Werner syndrome RecQ helicase-IN-2
    Inhibitor 99.32%
    Werner syndrome RecQ helicase-IN-2 (example 57) is a potent Werner syndrome RecQ DNA helicase enzyme (WRN) inhibitor and can be used in cancer research.
    Werner syndrome RecQ helicase-IN-2
Cat. No. Product Name / Synonyms Application Reactivity